5David PerezPresident
Blood Management CompanyBloodManagementCompany© Terumo Corporation

History of Long-Term Profitable Growth
Annual Blood Management Company Sales
Stable Growth

Rapid Global
Market Expansion

IndustryConsolidation andTransformation

Return to Growthin Existing andNew Markets

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

Sales prior to 2011 represent the pro forma combined pre-acquisition sales of Terumo Transfusion and CaridianBCT.
All historical sales are at actual FX rates and forward-looking sales are at 2016 Plan FX rates.

© Terumo Corporation

Dec. 12, 2016

1/8NEW CLINICAL HORIZONSShifting our Focus from Products to Disease-States and Medical Specialties

ONCOLOGYProduct

AUTOIMMUNEDISORDERS

DiseaseHEMATOLOGY© Terumo Corporation

REGENERATIVEMEDICINE

Dec. 12, 2016

2/8

GLOBAL MARKET LEADER POSITION
Growth Opportunities for Three Business Segments

Blood Centers

Therapeutic Systems

Delivering higher economic
Advancing blood therapies toand clinical value with strategic bring more treatment options
supply chain solutions
to patients© Terumo Corporation

Cell Processing

Enabling cellular therapies
that may fundamentally
improve outcomes

Dec. 12, 20163/8

Blood CentersLeverage Our Market Leadership
Delivering higher economic and clinical value
with strategic supply chain solutions

Mid-Single-Digit#1 Apheresis collections
 Informatics/software forblood center management
 Whole blood automation (WBA)#2 Pathogen reduction technologies
 Whole blood bags

© Terumo Corporation

GrowthTGBM Worldwide Sales
FY 2016 to FY 2021

Dec. 12, 2016

4/8

Therapeutic Systems
Advance Therapeutic Apheresis
Advancing blood therapies to bring moretreatment options to patients

Created and set the industry standard fortherapeutic apheresis devices

High-Single-Digit

GrowthTGBM Worldwide SalesFY 2016 to FY 2021

#1  Therapeutic plasma exchange Cell collections© Terumo Corporation

Dec. 12, 2016

5/8

Cell Processing
Unlocking the Potential of Cells
Enabling cellular therapies that may
fundamentally improve outcomes

Creating the market for the first automatedsystem designed to grow adherent andsuspension cells in a closed environment#1

Double Digit

GrowthTGBM Worldwide Sales
FY 2016 to FY 2021

 Point-of-Care injectable cell therapies
 Sterile connection devices
 Driving to be the first to market with endto-end immunotherapy solutions© Terumo Corporation

Dec. 12, 2016

6/8

Global Innovation and Development
24/7 for Maximum Internal Efficiency; Combined with 30 Global Partners
Fujinomiya
Filters Engineering
Plastics Engineering

Larne
Fluids Engineering
Process Engineering

Long Thanh
Process Engineering

Leuven/Zaventem
Hardware Engineering
Software Engineering

Lakewood
Hardware Engineering
Software Engineering
Plastics Engineering
Blood Science V&V
Process Engineering

Trivandrum
Hardware Engineering
Plastics Engineering
Blood Science V&V

V&V = verification and validation

Outsourcing Partners
Terumo BCT 24/7 global innovation and development
footprint with 30 external global partners© Terumo Corporation

Dec. 12, 20167/8

EVERY SECOND OF EVERY DAY
We Are Saving Lives HereCONTRIBUTING TO SOCIETY THROUGH HEALTHCARE© Terumo Corporation

Dec. 12, 20168/8

© Terumo Corporation

Disclaimer
The information that Terumo discloses and the forward-looking statements
including financial projections are based upon our assumptions using
information available to us at the time and are not intended to be guarantees offuture events or performance. Accordingly, it should be noted that actual
results may differ from those forecasts on projections due to various factors.
Factors affecting actual results include, but are not limited to, changes in
economic conditions surrounding Terumo, fluctuations of foreign exchange
rates, and state of the competition.
The market share information in this presentation is partly derived from ourown independent research.

© Terumo Corporation